Raval Amit D, Kistler Kristin D, Tang Yuexin, Vincenti Flavio
Merck & Co., Inc., Rahway, New Jersey, USA.
Xcenda, Inc., Carrollton, Texas, USA.
Transpl Infect Dis. 2023 Feb;25(1):e14000. doi: 10.1111/tid.14000. Epub 2023 Jan 19.
Leukopenia and neutropenia (L/N) may affect treatment decisions, potentially resulting in poor clinical and economic outcomes among kidney transplant recipients (KTRs). The burden of L/N is poorly quantified systematically. This systematic literature review aimed to summarize the incidence of, risk factors for, and clinical and economic outcomes associated with L/N post-KT.
We systematically searched MEDLINE, Embase, and the Cochrane Library (from database inception-June 14, 2021) and conferences (past 3 years) to identify observational studies examining epidemiology, risk factors, or outcomes associated with L/N among adult KTRs.
Of 2081 records, 82 studies met inclusion criteria. Seventy-three studies reported the epidemiology of L/N post-KT. Pooled incidence of neutropenia, defined as absolute neutrophil counts (ANC) <1000/μl, ranged from 13% to 48% within 1-year post-transplant; ANC <500/μl ranged from 15% to 20%. Leukopenia, defined as white blood cell counts <3500/μl, was 19% to 83%. Eleven studies reported independent risk factors associated with L/N post-KT. D+/R- cytomegalovirus status, mycophenolic acid (MPA), and tacrolimus use were the most consistent risk factors across studies. Fourteen studies reported L/N-associated clinical outcomes. We noted a trend toward a positive association between neutropenia and acute rejection/opportunistic infections. Mixed findings were noted on the association between L/N and graft failure or mortality. Dosage modifications of valganciclovir, MPA, cotrimoxazole, and anti-thymoglobulin and the need for granulocyte colony-stimulating factor (G-CSF) use were common with L/N.
Findings suggest post-transplant L/N were common and associated with frequent modifications of immunosuppressive agents, requiring G-CSF use, and rejection or opportunistic infections. Findings highlight the need for interventions to reduce risk of L/N post-KT.
白细胞减少症和中性粒细胞减少症(L/N)可能会影响治疗决策,这可能会导致肾移植受者(KTR)出现不良的临床和经济后果。L/N的负担尚未得到系统的量化。本系统文献综述旨在总结肾移植术后L/N的发生率、风险因素以及与之相关的临床和经济后果。
我们系统检索了MEDLINE、Embase和Cochrane图书馆(从数据库建立至2021年6月14日)以及会议(过去3年),以确定观察性研究,这些研究探讨了成年KTR中与L/N相关的流行病学、风险因素或结局。
在2081条记录中,82项研究符合纳入标准。73项研究报告了肾移植术后L/N的流行病学情况。中性粒细胞减少症(定义为绝对中性粒细胞计数(ANC)<1000/μl)在移植后1年内的合并发生率在13%至48%之间;ANC<500/μl的发生率在15%至20%之间。白细胞减少症(定义为白细胞计数<3500/μl)的发生率为19%至83%。11项研究报告了与肾移植术后L/N相关的独立风险因素。D+/R-巨细胞病毒状态、霉酚酸(MPA)和他克莫司的使用是各项研究中最一致的风险因素。14项研究报告了与L/N相关的临床结局。我们注意到中性粒细胞减少症与急性排斥反应/机会性感染之间存在正相关趋势。关于L/N与移植失败或死亡率之间的关联,研究结果不一。对于L/N,更昔洛韦、MPA、复方新诺明和抗胸腺细胞球蛋白的剂量调整以及使用粒细胞集落刺激因子(G-CSF)的情况很常见。
研究结果表明,移植后L/N很常见,并且与免疫抑制剂的频繁调整、需要使用G-CSF以及排斥反应或机会性感染有关。研究结果强调了采取干预措施以降低肾移植术后L/N风险的必要性。